GlassScriptPhysician profile
Joshua Kerstein
NPI 1689632523
$140,710.54
in general payments reported to CMS, 2019-2025
13 companies · $12K in 2025
The $12K reported for 2025 was more than what 95% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30K · 2020: $27K · 2021: $27K · 2022: $17K · 2023: $20K · 2024: $8,082 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $37K · Food and Beverage: $1,557 · Consulting Fee: $1,200 · Education: $9.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $36,563.00 |
| Food and Beverage | $1,557.31 |
| Consulting Fee | $1,200.00 |
| Education | $9.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $62,319.72 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $32,716.33 | 2019-2024 | Lokelma |
| E.R. Squibb & Sons, L.L.C. | $30,728.90 | 2019-2025 | Camzyos |
| Janssen Pharmaceuticals, INC | $10,506.34 | 2019-2023 | Xarelto |
| Lilly USA, LLC | $3,267.50 | 2020-2023 | Jardiance |
| Pfizer INC. | $390.42 | 2019-2021 | |
| Vifor Pharma, INC. | $212.09 | 2021 | |
| Irhythm Technologies, INC. | $172.70 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $156.78 | 2019-2024 | |
| Amgen INC. | $117.23 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $60.61 | 2021-2024 | Lifevest |
| Abbott Laboratories | $38.90 | 2021 | |
| Cook Medical LLC | $23.02 | 2025 | Zenith Alpha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Kerstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.